- Identification of Novel Compound Heterozygous Mutations in the ACADS Gene of an Asymptomatic Korean Newborn with Short Chain Acyl-CoA Dehydrogenase Deficiency by Tandem Mass Spectrometry
-
Cheon CK, Choi HS, Kim SY, Yoo HW, Kim GH
- KMID: 2055570
- J Genet Med.
- 2012 Jun;9(1):42-46.
- doi: 10.5734/JGM.2012.9.1.42
Short-chain acyl-CoA dehydrogenase deficiency (SCADD; OMIM # 201470) is an autosomal recessive inborn error of mitochondrial fatty acid beta-oxidation, presenting with a variety of clinical signs and symptoms. Developmental delay,... -
- CITED
-
- Close
- SHARE
-
- Close
- Randomized, Multicenter, Phase III Trial of Heptaplatin 1-hour Infusion and 5-Fluorouracil Combination Chemotherapy Comparing with Cisplatin and 5-Fluorouracil Combination Chemotherapy in Patients with Advanced Gastric Cancer
-
Lee KH, Hyun MS, Kim HK, Jin HM, Yang J, Song HS, Do YR, Ryoo HM, Chung JS, Zang DY, Lim HY, Jin JY, Yim CY, Park HS, Kim JS, Sohn CH, Lee SN
- KMID: 2165991
- Cancer Res Treat.
- 2009 Mar;41(1):12-18.
PURPOSE: Heptaplatin (Sunpla) is a cisplatin derivative. A phase IIb trial using heptaplatin resulted in a 34% response rate with mild nephrotoxicity. We conducted a randomized phase III trial of... -
- CITED
-
- Close
- SHARE
-
- Close
- Combination Chemotherapy with 5-Fluorouracil and Heptaplatin as First-line Treatment in Patients with Advanced Gastric Cancer
-
Min YJ, Bang SJ, Shin JW, Kim DH, Park JH, Kim GY, Ko BK, Choi DH, Cho HR
- KMID: 1786814
- J Korean Med Sci.
- 2004 Jun;19(3):369-373.
- doi: 10.3346/jkms.2004.19.3.369
Heptaplatin is a recently developed platinum derivative. This agent has been reported to have a response rate of 17% as a single agent, and tolerable toxicity in the treatment of... -
- CITED
-
- Close
- SHARE
-
- Close
